Amicus Therap Us Drug Patent Portfolio

Amicus Therap Us owns 2 orange book drugs protected by 68 US patents Given below is the list of Amicus Therap Us's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene 11 Jan, 2042
Active
US11633388 Methods of treating Fabry patients having renal impairment 25 Mar, 2039
Active
US11622962 Methods of treating Fabry patients having renal impairment 17 Mar, 2039
Active
US11642334 Methods of treating Fabry patients having renal impairment 20 Feb, 2039
Active
US11826360 Methods of treating Fabry patients having renal impairment 16 Feb, 2039
Active
US11357784 Use of migalastat for treating Fabry disease in pregnant patients 06 Feb, 2039
Active
US11903938 Methods of treating Fabry patients having renal impairment 17 Aug, 2038
Active
US10251873 Methods of treating fabry patients having renal impairment 30 May, 2038
Active
US10471053 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10792278 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10792279 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10799491 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10806727 Methods of treating fabry patients having renal impairment 30 May, 2038
Active
US10849889 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10849890 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10857141 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10857142 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10874655 Methods of treating fabry patients having renal impairment 30 May, 2038
Active
US10874656 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10874657 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11278536 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11278537 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11278538 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11278539 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11278540 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11304940 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11357761 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11357762 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11357763 Methods of treating fabry patients having renal impairment 30 May, 2038
Active
US11357764 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11357765 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11376244 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11389436 Methods of treating fabry patients having renal impairment 30 May, 2038
Active
US11389437 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11426396 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11458128 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11612593 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11612594 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11633387 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11666564 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11786516 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US11813255 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US12042488 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US12042489 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US12042490 Methods of treating Fabry patients having renal impairment 30 May, 2038
Active
US10857212 Augmented acid alpha-glucosidase for the treatment of Pompe disease 12 Aug, 2037
Active
US10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene 15 Mar, 2037
Active
US11234972 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene 15 Mar, 2037
Active
US11278601 Augmented acid alpha-glucosidase for the treatment of Pompe disease 29 Dec, 2036
Active
US10208299 Highly potent acid alpha-glucosidase with enhanced carbohydrates 30 Sep, 2035
Active
US10961522 Highly potent acid alpha-glucosidase with enhanced carbohydrates 30 Sep, 2035
Active
US11753632 Highly potent acid alpha-glucosidase with enhanced carbohydrates 30 Sep, 2035
Active
US10512677 High concentration alpha-glucosidase compositions for the treatment of pompe disease 07 Mar, 2033
Active
US11278599 High concentration alpha-glucosidase compositions for the treatment of Pompe disease 07 Mar, 2033
Active
USRE48608 Method to predict response to pharmacological chaperone treatment of diseases 20 Oct, 2031
Active
US10813921 Method to predict response to pharmacological chaperone treatment of diseases 12 Feb, 2029
Active
US8592362 Method to predict response to pharmacological chaperone treatment of diseases 12 Feb, 2029
Active
US9095584 Method to predict response to pharmacological chaperone treatment of diseases 12 Feb, 2029
Active
US10525045 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
Active
US10925866 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
Active
US11033538 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
Active
US9999618 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
Active
US10383864 Methods for treatment of Fabry disease 16 May, 2027
Active
US10406143 Methods for treatment of fabry disease 16 May, 2027
Active
US11241422 Methods for treatment of Fabry disease 16 May, 2027
Active
US9000011 Methods for treatment of Fabry disease 16 May, 2027
Active
US9480682 Methods for treatment of Fabry disease 16 May, 2027
Active
US9987263 Methods for treatment of Fabry disease 16 May, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Amicus Therap Us.

Activity Date Patent Number
Patent litigations
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jun, 2024 US10925866
Payment of Maintenance Fee, 4th Year, Large Entity 12 Jun, 2024 US10874655
Payment of Maintenance Fee, 4th Year, Large Entity 12 Jun, 2024 US10874657
Payment of Maintenance Fee, 4th Year, Large Entity 12 Jun, 2024 US10874656
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 05 Jun, 2024 US10874656
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 05 Jun, 2024 US10874657
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 05 Jun, 2024 US10874655
Payment of Maintenance Fee, 4th Year, Large Entity 22 May, 2024 US10857142
Payment of Maintenance Fee, 4th Year, Large Entity 22 May, 2024 US10857141
Payment of Maintenance Fee, 4th Year, Large Entity 22 May, 2024 US10857212
Payment of Maintenance Fee, 4th Yr, Small Entity 15 May, 2024 US10849889
Payment of Maintenance Fee, 4th Year, Large Entity 15 May, 2024 US10849890
Withdrawal of Application for PTE 13 May, 2024 US9000011
Letter from FDA or Dept of Agriculture re PTE application 08 May, 2024 US10208299
Payment of Maintenance Fee, 4th Yr, Small Entity 10 Apr, 2024 US10813921


Amicus Therap Us Drug Patents' Oppositions Filed in EPO

Amicus Therap Us drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 31, 2022, by Gill Jennings & Every Llp. This opposition was filed on patent number EP17714100A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17714100A May, 2022 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP17714100A May, 2022 Gill Jennings & Every LLP Granted and Under Opposition


Amicus Therap Us's Family Patents

Amicus Therap Us drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 40.4% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Amicus Therap Us Drug List

Given below is the complete list of Amicus Therap Us's drugs and the patents protecting them.


1. Galafold

Galafold is protected by 61 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene 11 Jan, 2042
(17 years from now)
Active
US11633388 Methods of treating Fabry patients having renal impairment 25 Mar, 2039
(14 years from now)
Active
US11622962 Methods of treating Fabry patients having renal impairment 17 Mar, 2039
(14 years from now)
Active
US11642334 Methods of treating Fabry patients having renal impairment 20 Feb, 2039
(14 years from now)
Active
US11826360 Methods of treating Fabry patients having renal impairment 16 Feb, 2039
(14 years from now)
Active
US11357784 Use of migalastat for treating Fabry disease in pregnant patients 06 Feb, 2039
(14 years from now)
Active
US11903938 Methods of treating Fabry patients having renal impairment 17 Aug, 2038
(13 years from now)
Active
US10251873 Methods of treating fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10471053 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10792278 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10792279 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10799491 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10806727 Methods of treating fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10849889 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10849890 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10857141 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10857142 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10874655 Methods of treating fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10874656 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10874657 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11278536 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11278537 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11278538 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11278539 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11278540 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11304940 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11357761 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11357762 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11357763 Methods of treating fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11357764 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11357765 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11376244 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11389436 Methods of treating fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11389437 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11426396 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11458128 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11612593 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11612594 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11633387 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11666564 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11786516 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US11813255 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US12042488 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US12042489 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US12042490 Methods of treating Fabry patients having renal impairment 30 May, 2038
(13 years from now)
Active
US10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene 15 Mar, 2037
(12 years from now)
Active
US11234972 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene 15 Mar, 2037
(12 years from now)
Active
USRE48608 Method to predict response to pharmacological chaperone treatment of diseases 20 Oct, 2031
(7 years from now)
Active
US10813921 Method to predict response to pharmacological chaperone treatment of diseases 12 Feb, 2029
(4 years from now)
Active
US8592362 Method to predict response to pharmacological chaperone treatment of diseases 12 Feb, 2029
(4 years from now)
Active
US9095584 Method to predict response to pharmacological chaperone treatment of diseases 12 Feb, 2029
(4 years from now)
Active
US10525045 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
(3 years from now)
Active
US10925866 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
(3 years from now)
Active
US11033538 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
(3 years from now)
Active
US9999618 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones 28 Apr, 2028
(3 years from now)
Active
US10383864 Methods for treatment of Fabry disease 16 May, 2027
(2 years from now)
Active
US10406143 Methods for treatment of fabry disease 16 May, 2027
(2 years from now)
Active
US11241422 Methods for treatment of Fabry disease 16 May, 2027
(2 years from now)
Active
US9000011 Methods for treatment of Fabry disease 16 May, 2027
(2 years from now)
Active
US9480682 Methods for treatment of Fabry disease 16 May, 2027
(2 years from now)
Active
US9987263 Methods for treatment of Fabry disease 16 May, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Galafold's drug page


2. Opfolda

Opfolda is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10857212 Augmented acid alpha-glucosidase for the treatment of Pompe disease 12 Aug, 2037
(12 years from now)
Active
US11278601 Augmented acid alpha-glucosidase for the treatment of Pompe disease 29 Dec, 2036
(12 years from now)
Active
US10208299 Highly potent acid alpha-glucosidase with enhanced carbohydrates 30 Sep, 2035
(10 years from now)
Active
US10961522 Highly potent acid alpha-glucosidase with enhanced carbohydrates 30 Sep, 2035
(10 years from now)
Active
US11753632 Highly potent acid alpha-glucosidase with enhanced carbohydrates 30 Sep, 2035
(10 years from now)
Active
US10512677 High concentration alpha-glucosidase compositions for the treatment of pompe disease 07 Mar, 2033
(8 years from now)
Active
US11278599 High concentration alpha-glucosidase compositions for the treatment of Pompe disease 07 Mar, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opfolda's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List